Stockscreener 앱 받기
13.00
6.21%
0.76
전일 마감가:
$12.24
열려 있는:
$12.25
하루 거래량:
532.19K
Relative Volume:
1.31
시가총액:
$803.05M
수익:
순이익/손실:
주가수익비율:
-
EPS:
-
순현금흐름:
1주 성능:
-4.34%
1개월 성능:
-30.41%
6개월 성능:
+0.00%
1년 성능:
+0.00%
1일 변동 폭
$0.00
$0.00
1주일 범위
$12.07
$14.41
52주 변동 폭
$12.07
$49.97
Obsidian Therapeutics, Inc. Common Stock Stock (OBX) Company Profile
Compare OBX vs VRTX, MRNA, REGN, ARGX, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
OBX
Obsidian Therapeutics, Inc. Common Stock
|
13.00 | 803.05M | 0 | 0 | 0 | 0.00 |
VRTX
Vertex Pharmaceuticals Inc
|
510.08 | 129.29B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
225.00 | 89.83B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
746.54 | 76.86B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
825.03 | 51.88B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
189.76 | 40.67B | 742.00K | -1.37B | -1.07B | -7.0731 |
Obsidian Therapeutics, Inc. Common Stock Stock (OBX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-09-22 | 개시 | Leerink Partners | Outperform |
| 2026-09-09 | 개시 | William Blair | Outperform |
| 2026-08-06 | 개시 | TD Cowen | Buy |
| 2026-08-05 | 개시 | Piper Sandler | Overweight |
Obsidian Therapeutics, Inc. Common Stock 주식(OBX)의 최신 뉴스
Paradigm BioCapital Reports 6.6% Ownership Stake in Obsidian Therapeutics - Kalkine Media
A passive investor reports 4.1M shares of Obsidian Therapeutics (OBX). - Stock Titan
Iovance Biotherapeutics (NasdaqGM:IOVA) Stock Forecast & Analyst Predictions - Simply Wall Street
Obsidian Therapeutics, Inc.(NasdaqCM: OBX) added to S&P TMI Index - marketscreener.com
A booming business on Wall Street would love more biotechs to quietly die - BioPharma Dive
William Blair initiates Obsidian Therapeutics stock with outperform rating - Investing.com
Obsidian TherapeuticsFiles Prospectus Relates To Resale Of Up To 29,164,045 Shares Of Common Stock By Selling Stockholders- SEC Filing - TradingView
Werewolf Therapeutics and Ambros Therapeutics Announce Merger Agreement and Concurrent Oversubscribed $150 Million Private Placement - Yahoo Finance
Obsidian Therapeutics (OBX) director Heidi Hagen reports 517,500 option shares - Stock Titan
Tenax Therapeutics (NASDAQ:TENX) Drops 85% as Phase 3 LEVEL Study Fails to Meet Main Endpoints - TechStock²
symbol__ Stock Quote Price and Forecast - CNN
Obsidian Therapeutics (OBX) 10K Form and Latest SEC Filings 2026 - MarketBeat
Octagon Capital Advisors2026 Investor Profile, Portfolio, Team & Investment Trends - Tracxn
OBX News Today | Why did Obsidian Therapeutics stock go up today? $OBX - MarketBeat
Obsidian Therapeutics (OBX) Stock Chart and Price History 2026 $OBX - marketbeat.com
Obsidian Therapeutics (OBX) Stock Price, News & Analysis $OBX - MarketBeat
Obsidian Therapeutics Announces First Patient Enrolled in the Registration-enabling Cohort of Phase 1/2 Agni-01 Study Evaluating Amsoki-cel (OBX-115) in Advanced Melanoma - Business Wire
TCGX Acquisition Corp. (TCGX) stock price, news, quote and history - Yahoo Finance UK
Obsidian Therapeutics, Inc. (OBX) balance sheet – Yahoo Finance - Yahoo Finance Singapore
Obsidian Therapeutics Completes Closing of Transaction with Galera Therapeutics and Previously Announced Private Placement of $350 Million - Business Wire
Obsidian Therapeutics completes merger with Galera - Investing.com
Obsidian Therapeutics Completes Galera Merger and $350 Million Financing - citybiz
Obsidian Therapeutics completes merger with Galera By Investing.com - Investing.com India
Oak Hill Bio and Research Alliance Corporation III Announce Business Combination Agreement to Create Publicly Listed Rare Disease Biotechnology Company to Advance Antisense Oligonucleotide Therapy Rugonersen for Angelman Syndrome - Yahoo Finance
Curis (CRIS) FDA Approvals, PDUFA Dates & Drug Alerts 2026 $CRIS - MarketBeat
Galera Flags Material Rights Change, But Details Remain a Mystery for Investors - finance.biggo.com
Halper Sadeh LLC is Investigating Whether LEG, AVNS, SEM, GRTX are Obtaining Fair Deals for their Shareholders - GlobeNewswire
Obsidian Therapeutics to Present OBX-115 Phase 2 Clinical Data in Advanced Melanoma in Oral Presentation at 2026 ASCO Annual Meeting - Business Wire
Obsidian, Galera to advance cell therapy following reverse merger - BioPharma Dive
Obsidian Therapeutics and Galera Therapeutics Enter $350 Million Merger Agreement - pharmexec.com
Obsidian and Galera reveal reverse merger plan - The Pharma Letter
Galera Therapeutics and Obsidian Therapeutics Announce - GlobeNewswire
GRTX Stock Alert: Halper Sadeh LLC is Investigating Whether Galera Therapeutics, Inc. is Obtaining a Fair Price for its Shareholders - Business Wire
enGene Therapeutics (Nasdaq:ENGN)Stock Analysis - Simply Wall Street
GALERA THERAPEUTICS (GRTX) Stock Price, News & Analysis - Stock Titan
Annual Financial Report07:00:05 30 Mar 2025RTW News article - London Stock Exchange
Iovance: The Company Makes It Hard To Estimate Revenue Growth (NASDAQ:IOVA) - Seeking Alpha
Obsidian Therapeutics Announces FDA Fast Track Designation for OBX-115 for the Treatment of Advanced Melanoma - Business Wire
Obsidian Therapeutics, Inc. Common Stock (OBX) 재무 분석
Obsidian Therapeutics, Inc. Common Stock (OBX)에 대한 금융 데이터가 없습니다. 더 많은 정보를 위해 다른 주식을 확인해보세요.
매출
순이익
현금흐름
주당 순 이익
0.41%
자본화:
|
볼륨(24시간):